A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
← catalyst calendarNCT07459634 · readout in 530 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Ireland Limited.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-30 | estimated | When the study began enrolling |
| Primary completion | 2028-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive-stage Small-cell Lung Cancer
Interventions
- Drug: Lurbinectedin — also filed as Zepzelca
- Drug: Durvalumab — also filed as Imfinzi
Primary outcome
what the primary-completion date above is the date OFInvestigator assessed PFS rate
measured 6 months
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed